{"schema_version":"secwatch.filing_event.v1","accession":"0001178253-25-000006","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.938926+00:00","generated_at":"2026-05-17T03:41:15.644206+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment","bullets":["Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.","Additional $2.3M payment from GSK for wind-down and termination activities.","SCYNEXIS will transfer BREXAFEMME NDA to GSK by end of 2025; GSK plans FDA interactions in 2026 for VVC/rVVC relaunch.","Milestones and royalties for VVC and rVVC indications remain unchanged under the exclusive license agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001178253-25-000006","json":"https://secwatch.observer/filing/0001178253-25-000006.json","markdown":"https://secwatch.observer/filing/0001178253-25-000006.md","text":"https://secwatch.observer/filing/0001178253-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000117825325000006/0001178253-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000117825325000006/scyx-20251014.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:41:15.644206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}